Meals and snacks labeled “GLP-1 Friendly” are appearing more often in U.S. supermarkets in 2024 and 2025 as weight-loss drugs such as Wegovy and Zepbound become widely used. These medicines copy the hormone GLP-1, which reduces appetite and affects digestion, leading many users to eat much smaller portions. A study by the Kaiser Family Foundation reported that about 12 percent of U.S. adults were using GLP-1 drugs by late 2024 for weight loss or diabetes care. Food companies responded to this prevalent change by promoting meals designed for smaller portions and higher nutrition. However, the term is not regulated by the U.S. Food and Drug Administration, meaning the label does not guarantee clear health standards or medical approval.

Nutrition experts say eating habits matter more than special packaging. Because GLP-1 drugs reduce hunger, each meal should provide enough protein, fiber, and fluids to mitigate common side effects. Dietitians from large medical centers recommend around 20 to 30 grams of protein per meal and regular fiber intake to support digestion. Some packaged foods meet these goals, but shoppers are advised to scrutinize labels for high fat, sugar, or sodium levels. Recent product launches from Nestlé and Conagra show how the food industry is adapting. The broader implications include easier meal planning, but long-term results depend on balanced diets and professional guidance for substantial health benefits. Experts also note that clear nutrition education helps consumers make safer choices while using medications daily.